

PRESS RELEASE

Lund December 7, 2020

Extended SpagoPix patent protection in Europe

Spago Nanomedical AB (publ) has received notice from the European Patent Office (EPO) that it intends to grant the company's patent application including a critical component of the SpagoPix candidate drug SN132D. The granted patent will extend protection of SpagoPix in Europe until at least 2038.

EPO has issued an Intention to grant-notification which means the patent will be granted following confirmation of Spago Nanomedical and payment of applicable fees. The granted patent, "Chemical compounds for coating of nanostructures" (EP18700364.5) provides Spago Nanomedical with additional protection for SpagoPix in Europe, the second largest market for MRI contrast agents. The patent contains claims for the proprietary coating material that is part of the company's unique nano-particles. The granted patent provides extended market exclusivity for SpagoPix in Europe until at least 2038.

The patent application has been submitted in additional countries, including USA and Japan.

For further information, please contact Mats Hansen CEO Spago Nanomedical AB, +46 46 81188, mats.hansen@spagonanomedical.se.

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company's development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical's share is listed on Spotlight Stock Market in Stockholm (ticker: SPAG). For further information, see www.spagonanomedical.se.

The information in this press release is such that Spago Nanomedical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU, 596/2014). The information was submitted for publication, through the agency of the contact person set out above, on December 7, 2020.